VVOS Stock Overview A medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Vivos Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Vivos Therapeutics Historical stock prices Current Share Price US$4.98 52 Week High US$12.83 52 Week Low US$1.91 Beta 7.64 1 Month Change 55.63% 3 Month Change 69.97% 1 Year Change -56.05% 3 Year Change -92.73% 5 Year Change n/a Change since IPO -97.78%
Recent News & Updates See more updates
Consensus EPS estimates upgraded to US$2.02 loss, revenue downgraded Nov 21
Price target decreased by 14% to US$6.30 Nov 20
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 17
New major risk - Financial position Nov 17
Vivos Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 14
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely Nov 12
Vivos Therapeutics, Inc., Annual General Meeting, Nov 26, 2024 Sep 19
New major risk - Share price stability Sep 19
Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring Sep 18
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story Sep 10
Consensus estimates of losses per share improve by 31% Aug 21
New major risk - Financial position Aug 16
Vivos Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 14
Vivos Therapeutics Announces Positive Results from 7-Month Multi-Site Pilot of Its New Provider-Based Marketing and Distribution Model Jun 28 Vivos Therapeutics, Inc. announced that it has received $7.5 million in funding Jun 13
Vivos Therapeutics Provides Non-Compliance Update May 18
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 16
Vivos Therapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024 May 16
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks Apr 25
New major risk - Shareholder dilution Apr 05
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 31
Vivos Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024 Mar 29
Vivos Therapeutics, Inc. Receives FDA Clearance to Vivos Care Oral Appliances to Treat Severe OSA in Adults Feb 07
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks Feb 02
Vivos Therapeutics, Inc. Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA Jan 10
Vivos Therapeutics, Inc. Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea Nov 30
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 17
Price target decreased by 7.7% to US$45.00 Nov 15
High number of new and inexperienced directors Nov 15
Vivos Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 10 Vivos Therapeutics, Inc. announced that it has received $4.000003 million in funding Nov 03
Vivos Therapeutics, Inc. announced that it expects to receive $4.000003 million in funding Nov 01
Vivos Therapeutics Provides Nasdaq Compliance Update Oct 28
Vivos Therapeutics Receives a Written Notice from the Nasdaq Sep 22
Vivos Therapeutics, Inc., Annual General Meeting, Sep 22, 2023 Aug 29
Vivos Therapeutics Receives Non-Compliance Letterer from Nasdaq Aug 22 Vivos Therapeutics, Inc. announced delayed 10-Q filing Aug 17
High number of new and inexperienced directors Aug 15
Vivos Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 11
Vivos Therapeutics, Inc. to Report Q1, 2023 Results on Jun 08, 2023 Jun 07
Vivos Therapeutics Receives Staff Deficiency Notice from The Nasdaq Stock Market Due to Failure to File its Form 10-Q May 29 Vivos Therapeutics, Inc. announced delayed 10-Q filing May 16
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS) Apr 18
Consensus EPS estimates upgraded to US$0.40 loss Apr 11
Price target decreased by 17% to US$1.88 Apr 04
No longer forecast to breakeven Apr 02
Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.26 loss in 3Q 2021) Jan 31
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements Jan 23
Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance of its DNA Oral Appliance for Treatment of Obstructive Sleep Apnea Jan 05
Vivos Therapeutics, Inc. to Report Q3, 2022 Results on Dec 20, 2022 Dec 17
Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q Nov 30
Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q Nov 29
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint Nov 27
High number of new and inexperienced directors Nov 16
Vivos Therapeutics Receives a Staff Deficiency Notice from The Nasdaq Stock Market Nov 07
Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q Aug 27
Vivos Therapeutics again delays Q2 2022 results Aug 23
Vivos Therapeutics, Inc. announced delayed 10-Q filing Aug 16
Vivos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 10
Vivos Therapeutics, Inc. Receives Multiple Class I Clearances by Therapeutic Goods Administration (TGA) of Australia Jul 19 Vivos Therapeutics, Inc., Annual General Meeting, Aug 25, 2022
Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada Jun 29
Vivos Therapeutics, Inc. Presents Positive Results from a Retrospective Study with Vivos Patients Jun 15
Consensus revenue estimates fall by 25% May 23
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be May 21
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint May 17
Price target decreased to US$9.00 Apr 27
High number of new and inexperienced directors Apr 27
No longer forecast to breakeven Apr 07
Consensus revenue estimates fall by 12% Apr 07
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 02
Price target decreased to US$9.88 Apr 01
Vivos Therapeutics, Inc. to Report Q4, 2021 Results on Mar 31, 2022 Apr 01
Vivos Therapeutics: First Take After The Broad Market Sell-Off Mar 06
Vivos Therapeutics, Inc. Announces Termination of G. Dave Singh, Chief Medical Officer Mar 03
Vivos Therapeutics, Inc. Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric Jan 28
Vivos Therapeutics Announces 18X Increase in Sleep Apnea Diagnostic Testing by Vivos Dentists Using Sleepimage Technology Jan 20
Forecast to breakeven in 2024 Jan 02
Third quarter 2021 earnings released: US$0.26 loss per share (vs US$0.16 loss in 3Q 2020) Nov 18
Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company's Technology for Obstructive Sleep Apnea Sep 24
FDA Grants 510(k) Market Clearance to Vivos Therapeutics’ mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea Aug 25 Shareholder Returns VVOS US Healthcare US Market 7D 8.0% -4.1% -2.4% 1Y -56.0% -10.2% 23.4%
See full shareholder returns
Return vs Market: VVOS underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is VVOS's price volatile compared to industry and market? VVOS volatility VVOS Average Weekly Movement 11.4% Healthcare Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: VVOS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VVOS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.
Show more Vivos Therapeutics, Inc. Fundamentals Summary How do Vivos Therapeutics's earnings and revenue compare to its market cap? VVOS fundamental statistics Market cap US$24.08m Earnings (TTM ) -US$12.57m Revenue (TTM ) US$14.58m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VVOS income statement (TTM ) Revenue US$14.58m Cost of Revenue US$5.57m Gross Profit US$9.01m Other Expenses US$21.58m Earnings -US$12.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.60 Gross Margin 61.80% Net Profit Margin -86.19% Debt/Equity Ratio 0%
How did VVOS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 12:18 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Vivos Therapeutics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Scott Henry Alliance Global Partners Edward Woo Ascendiant Capital Markets LLC Lucas Ward Ascendiant Capital Markets LLC
Show 2 more analysts 
